1. Scrip
  2. >>Business
  3. >>Earnings

Regeneron Has Strong Showing, But No REGEN-COV Sales Expected In First Half

Analysts Highlight Potential Growth Opportunities

 
• By Alaric DeArment

Dupixent sales grew by more than 50% as Eylea and REGEN-COV also drove sales growth, though the antiviral advantage will vanish due to the FDA restricting its use.

4th quarter computer key on key board
Regeneron reported its fourth quarter and full year 2021 sales on 4 February • Source: Shutterstock

Regeneron Pharmaceuticals, Inc. capped off 2021 squeezing one last bit of juice from its COVID-19 antibody cocktail, which along with Eylea (aflibercept) and Sanofi-partnered Dupixent (dupilumab) helped generate much of the company’s sales growth – but the company anticipates no revenue in the near term from the Roche Holding AG-partnered cocktail, REGEN-COV/Ronapreve (casirivimab/imdevimab) due to lack of efficacy against Omicron. Instead, management is playing up the potential for long-term sales growth in its pipeline.

On 4 February, the company reported fourth quarter 2021 revenues of $5bn and full year revenues of $16.1bn, respectively increases of 104% and 89% over the comparable periods of 2020. Of that, REGEN-COV accounted for $2.3bn for the quarter and $5

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

More from Business

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.